Autonomix proposes wide reverse stock split authority
Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
DEF 14A
Rhea-AI Filing Summary
Autonomix Medical, Inc. (AMIX) is asking stockholders at the October 29, 2026 annual meeting to re-elect six directors, ratify Forvis Mazars, LLP as auditor, approve Board discretion to implement a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-25 within one year, and approve an amended and restated 2023 Equity Incentive Plan that increases shares authorized for issuance. There were 1,959,938 shares of common stock outstanding as of September 8, 2026, each with one vote.
The company highlights prior reverse splits in October 2024 (1-for-20) and June 2026 (1-for-21), notes that authorized common shares will remain at 500,000,000, and discloses significant potential issuance capacity via options, warrants and plan shares. Governance disclosures describe a majority-independent board, three key board committees, anti-hedging and insider trading policies, and a Dodd-Frank compliant clawback policy. The proxy also details 2026 executive pay, bonuses tied to achieving corporate milestones, and new restricted stock awards granted in September 2026.
Positive
- None.
Negative
- Multiple reverse stock splits and large unused authorization: Autonomix completed 1-for-20 and 1-for-21 reverse splits in 2024 and 2026, and is now seeking authority for another 1-for-2 to 1-for-25 split while keeping 500,000,000 common shares authorized, which the company notes could increase available shares and have potential dilutive or anti-takeover effects.
